Individuals with MS often experience a gamut of urinary symptoms, from incontinence to chronic urinary tract infections to urinary hesitancy. As with other MS symptoms, urinary dysfunction can evolve as…
Read More
Dr. Mark Skeen, Director of Clinical Research and Education for the Duke Center for Research in Autoimmunity and Multiple Sclerosis (DREAMS), has organized a Multiple Sclerosis Mini-fellowship. Simon and Stephanie…
Sometimes the larger value of a research project isn’t immediately obvious, but research often produces discoveries with unanticipated relevance to other fields. A prime example of this is the work…
It’s not known why a percentage of MS patients don’t respond to the drug interferon-β. Knowing more about this phenomenon has the potential to 1) improve drug choice strategies for…
Monday was an energizing and exciting day for Discovery MS. We celebrated the conclusion of five years of participant enrollment in the MURDOCK Multiple Sclerosis…
Betaseron (interferon β-1b, or IFNβ) was the very first MS drug, and it remains a first-line treatment for relapsing-remitting MS. Unfortunately, however, a percentage of MS patients don’t respond to…
Some MS symptoms are talked about less than others, and sexual dysfunction is one of these. The authors of this paper recognized the disease burden of sexual dysfunction to MS…
Selecting a disease-modifying drug for the treatment of MS is a crucial and oftentimes difficult decision. The researchers in this article in PLOS ONE sought to define the drug characteristics…
Thank you for your interest in Discovery MS.